All In Biotech

Drug Trial Radar · NCT04049331

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Mar 22, 2021

Primary completion

Jan 30, 2027

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Seattle Institute for Biomedical and Clinical ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 54 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.

Conditions

  • Hypogonadism, Male
  • Fatigue Syndrome, Chronic

Interventions

  • Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]Drug

    first two doses four weeks apart; following three more doses every ten weeks.

  • placeboOther

    first two doses four weeks apart; following three more doses every ten weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fatigue changeTime frame: 9 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Veterans Affairs Puget Sound Health Care System

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.